Category Specific RSS

Categories: News

Testing confirms infection resistance, First Graphene signs face mask supply deal

As world populations seek increased protection from airborne infections, advanced materials company First Graphene (ASX: FGR) has completed initial testing of their graphene as coating into protective equipment with excellent results. 

The testing was done in collaboration with planarTECH and their personal protective equipment (PPE) which confirmed anti-static and bacteria-resistant properties. With these results, planarTECH has entered into a 2-year supply contract to use  PureGRAPH® in their 2AM brand face masks. 

“planarTECH have moved very quickly to test and commercialise their new range of graphene face masks and we are pleased to support the growth of this product. Further opportunities exist in the development of planarTECH’s other PPE equipment,” said First Graphene CEO, Craig McGuckin. 

Having secured the supply agreement, planarTech will commence large-scale production of their protective face marks which will be coated with PureGRAPH®10.

Under terms of the agreement, First Graphene will supply one tonne of PureGRAPH®10 through each year of the agreement. 

“We have experienced substantial, rapid and qualified enquiries for the graphene mask,” said planarTECH Chairman, Ray Gibbs.  

“The 35 or so we are pursuing all require a fast turnaround of 2-3 weeks where potential orders could be very significant. This increasing demand has meant we needed to secure a robust graphene supply to ensure we met the known market demand.”

Produced out of First Graphene’s West Australian manufacturing facility, graphene powders are high-performance additives which are engineered byproducts of graphite which boast its strongest properties – strength, conductivity and lubrication – but as a significantly thinner single-layer material. 

Upon news of the supply agreement, FGR shares rose to a high of $0.15 in the first 30 minutes of morning trade, a 15% rise on their previous day close of $0.13.

Alfred Chan

Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.

Recent Posts

Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US

Atomo Diagnostics (ASX:AT1) has secured a significant new order for its patented Pascal cassette, with…

1 week ago

June 2025 quarter CPI no roadblock to August RBA rate cut

The June 2025 quarter CPI data released today were cheered by mortgage holders and share…

2 weeks ago

Vection Secures $7.3M Defence Extension as AI Demand Strengthens

AI Gains Ground in Defence Sector As governments increase investment in defence technology, AI-powered tools…

3 weeks ago

Calix Secures $44.9m ARENA Grant to Build Green Iron Plant with ZESTY Technology

Calix Limited (ASX:CXL) has taken a significant leap forward in developing Australia’s low-emissions steel value…

3 weeks ago

Harris Technology boosts retail margins in FY25 through growth of refurbished tech

Online tech retailer Harris Technology (ASX: HT8) has delivered a strong lift in gross product…

4 weeks ago

Lumos Diagnostics Secures US$317M Deal to Distribute FebriDx® in U.S.

In a significant move set to reshape rapid diagnostics in the U.S., ASX-listed Lumos Diagnostics…

4 weeks ago